Abbott Laboratories (ABT)
NYSE: ABT · Real-Time Price · USD
93.86
+1.06 (1.14%)
At close: Apr 28, 2026, 4:00 PM EDT
93.90
+0.04 (0.04%)
After-hours: Apr 28, 2026, 7:59 PM EDT
Abbott Laboratories Stock Forecast
Stock Price Forecast
The 20 analysts with 12-month price forecasts for Abbott Laboratories stock have an average target of 130.9, with a low estimate of 115 and a high estimate of 148. The average target predicts an increase of 39.46% from the current stock price of 93.86.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Abbott Laboratories stock from 20 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 7 | 10 |
| Buy | 7 | 7 | 8 | 8 | 8 | 8 |
| Hold | 2 | 2 | 2 | 2 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 18 | 18 | 19 | 19 | 17 | 20 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| BTIG | BTIG | Strong Buy Reiterates $131 | Strong Buy | Reiterates | $131 | +39.57% | Apr 27, 2026 |
| Barclays | Barclays | Buy Maintains $144 → $143 | Buy | Maintains | $144 → $143 | +52.35% | Apr 20, 2026 |
| Piper Sandler | Piper Sandler | Buy Maintains $135 → $115 | Buy | Maintains | $135 → $115 | +22.52% | Apr 17, 2026 |
| Oppenheimer | Oppenheimer | Buy Maintains $132 → $115 | Buy | Maintains | $132 → $115 | +22.52% | Apr 17, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $135 → $130 | Buy | Maintains | $135 → $130 | +38.50% | Apr 17, 2026 |
Financial Forecast
Revenue This Year
49.09B
from 44.33B
Increased by 10.75%
Revenue Next Year
53.07B
from 49.09B
Increased by 8.10%
EPS This Year
5.70
from 3.72
Increased by 53.29%
EPS Next Year
6.28
from 5.70
Increased by 10.19%
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 53.3B | 58.5B | |||||
| Avg | 49.1B | 53.1B | |||||
| Low | 46.4B | 49.7B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 20.2% | 19.1% | |||||
| Avg | 10.7% | 8.1% | |||||
| Low | 4.6% | 1.3% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 6.06 | 6.70 | |||||
| Avg | 5.70 | 6.28 | |||||
| Low | 5.33 | 5.94 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 |
|---|---|---|---|---|---|---|---|
| High | 62.9% | 17.5% | |||||
| Avg | 53.3% | 10.2% | |||||
| Low | 43.3% | 4.1% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.